drugset / Trial / NCT01882907

Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

NCT01882907

Phase 4 Completed 287 enrolled Pusan National University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Timeline

Start
2009-12
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pioglitazone Small molecule 15 mg
Subject Vildagliptin Other / unclassified 50 mg